Tumor Treating Fields (TTFields) were pioneered by Dr. Yoram Palti, MD, PhD, Professor Emeritus of Physiology and Biophysics at the Technion – Israel Institute of Technology. More than two decades of published research have explored the biological mechanisms, safety, dosimetry, and clinical potential of TTFields across multiple solid tumors.

Published research indicates that TTFields affect cancer cells through multiple mechanisms, including disruption of the mitotic spindle and cytokinesis during cell division, interference with DNA-damage repair, and activation of immune-related pathways.

Specially tuned TTFs are sent through cancer cells while they’re dividing. These fields interact with charged particles inside the cells—called dipoles—which have a positive charge on one end and a negative charge on the other. As the electric field alternates, it causes these particles to move back and forth, disrupting their normal function and preventing the cancer cells from dividing properly.

Cells that undergo division while exposed to TTF are damaged in the process and exhibit clear signs of cellular distress.

Dr. Kenneth Swanson's full scientific presentation via YouTube: 

Evidence suggests that the stress experienced by cancer cells dividing under TTF triggers an immune response, leading to cell death and contributing to tumor reduction.